Drugs / Syngeneic Lymphocytes (CD4+)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001535 | Mar 1996 → Mar 2002 | AIDS, Kaposi's sarcoma | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Syngeneic Lymphocytes (CD4+) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001535 ↗ |
| Modality | Cell therapy | “genetically altered T lymphocytes (white blood cells of the immune system)” NCT00001535 ↗ |
| Route | Intravenous | “They are then infused intravenously (through a vein) into the infected twin.” NCT00001535 ↗ |